Madison, NJ, United States
Madison, NJ, United States

Time filter

Source Type

SALT LAKE CITY--(BUSINESS WIRE)--Atlantic Health System, a leading non-profit, clinically integrated health care system in New Jersey, will use Central Logic’s technology solution to support the Comprehensive Care for Joint Replacement (CJR) bundled payments program implemented by the Centers for Medicare & Medicaid Services. Central Logic collaborated with Atlantic Health System to develop Central Logic Patient Connect™, the first web-based technology to operationalize care coordination. The software will organize data for patients as they transition from hospital care and ensure that follow-up care is delivered. “The relationship between Central Logic and Atlantic Health System is based on a shared mission of improving patient care,” said Jennifer Holmes, Central Logic CEO and President. “Atlantic Health System will be able to use our technology solution, Patient Connect™, for patients undergoing knee and hip replacements and expand the scope of follow-up care to reduce the likelihood that these patients will need to be readmitted to the hospital. When combined with our Transfer Center solution, Atlantic Health System will have information on the entire episode of care and provide valuable data from inside and outside of the hospital’s four walls. We are proud to collaborate with Atlantic Health System on this innovative effort.” Atlantic Health System was instrumental in the development of a CJR module for Central Logic Patient Connect™. Using the technology solution will allow Atlantic Health System to track both preoperative and postoperative patients and make better predictions once those patients are discharged. In November 2015, CMS enacted The Comprehensive Care for Joint Replacement (CJR) model, designed to reduce cost and promote better patient outcomes though streamlined coordination of care for Medicare patients receiving hip and knee replacement surgery. Atlantic Health System has been participating in this bundling initiative since its inception in April, 2016. “Our promise to our communities is that all who enter our system will receive the highest quality care delivered at the right time, at the right place, and at the right cost,” said Jim Smith, administrator of bundle payment models for Atlantic Health System. “We have had the strategy and structure in place. With Central Logic Patient Connect™, we now have the technology to more efficiently fulfill our commitment. Central Logic Patient Connect is a robust technology solution and implementing it at Atlantic Health System will not only increase the productivity and capability of our staff, but it will help to ensure quality of care and reduce readmissions, among other benefits.” “We ultimately want patients to be placed back in their homes and then provide those patients with the resources to be comfortable and recuperating successfully. I believe our system and Central Logic Patient Connect™ will help us meet this goal.” Additionally, utilizing Central Logic Patient Connect™ will help Atlantic Health System streamline how patients move through the continuum of care to improve outcomes including reduced lengths of stay and readmissions as well as better overall patient experiences. Central Logic Patient Connect™ also will create operational efficiencies and allow the system’s care navigators to oversee a larger population of patients while maintaining and improving the quality of patient care. Atlantic Health System and Central Logic continue to work closely to determine the next use cases for Patient Connect About Central Logic: Central Logic is a leading innovative healthcare software solutions company that offers a comprehensive “end to end” suite of solutions that captures key patient information from inside and outside the hospital’s four walls to provide real-time visibility throughout a patient’s care continuum journey. Its flagship innovation, Central Logic Patient Connect™, was launched in 2016 and is one in Central Logic’s “end to end” suite of software solutions that connects, captures, and reports on critical patient care issues. Founded in 2005, Central Logic works collaboratively with more than 500 hospitals and thousands of healthcare professionals – including physicians, administrators and healthcare staff – to help hospitals and systems standardize processes, centralize actionable data and operationalize care coordination. Atlantic Health System, headquartered in Morristown, New Jersey, is a leading non-profit, clinically integrated health care system comprised of Atlantic Medical Group with more than 900 physicians and multispecialty care providers, medical centers, rehabilitation and urgent care. Atlantic Medical Group had more than 1.2 million patient visits in 2016. Locations include Morristown Medical Center in Morristown, NJ; Overlook Medical Center in Summit, NJ; Newton Medical Center in Newton, NJ; Chilton Medical Center in Pompton Plains, NJ; Hackettstown Medical Center in Hackettstown, NJ; and Goryeb Children’s Hospital in Morristown, NJ, as well as Atlantic Rehabilitation Institute, and Atlantic Home Care and Hospice. It also includes its subsidiary, Atlantic Ambulance Corporation. Atlantic Health System comprises 1,747 licensed beds, nearly 16,000 employees and more than 3,700 physicians. Atlantic Health System has a medical school affiliation with the Sidney Kimmel Medical College at Thomas Jefferson University; is part of Atlantic Accountable Care Organization, one of the largest ACOs in the nation, and is a member of AllSpire Health Partners.


News Article | May 23, 2017
Site: www.prnewswire.com

Guadagno is New Jersey's first ever Lieutenant Governor, an office she has held since 2009.  She also serves as the state's Secretary of State.  Prior to being elected to her first statewide office, Guadagno served as a former Assistant United States Attorney for the Eastern District of New York and the District of New Jersey.   She was also deputy chief of the United State Attorney's Office's corruption unit from 1994-1998.  During her tenure there, she brought successful prosecutions against both Republicans and Democrats. Maoli states, "As a candidate for governor, Guadagno understands what is needed in New Jersey for business and the people of this state, and she clearly has her priorities in order."  She has called for cuts in property taxes and has promised to veto any tax increases.  She notably fought Governor Christie's decision to raise the gasoline tax by 23 cents a gallon last year.  She has also called for a property tax "circuit breaker," which will impose a five percent ceiling on the school portion of New Jersey homeowners' property taxes.  She has also promised to renegotiate the state's pension and health benefits to ensure that state workers receive pensions that are equivalent to the private sector. "Kim is the real deal and the best choice for this job.  I'm sure when the people of New Jersey get to know her, they'll see cares about the people of New Jersey, families, and she is beholden to no one but the tax payers.  Most important, she is the best answer to the state's economic health and future." In addition to his automotive empire, which includes Whippany based Lexus of Route 10, Alfa Romeo of Morris County, Maserati of Morris County, plus BMW Springfield, Maserati of Bergen County, and Mercedes Benz of Goldens Bridge, New York, Maoli also has major real estate holdings in the state.  He is recognized as a philanthropist, most recently, donating his Alnwick Hall abbey to the Women's Association for Morristown Medical Center to be this year's host estate for its "Mansions in May" fundraiser.  He also recently sponsored Tony winner Melba Moore's appearance at Montclair State University to headline its annual benefit concert for Autism New Jersey. Maoli's involvement in politics is not new.  In 2009, he was a member of the Executive Finance Committee for the New Jersey Governor Chris Christie.  In 2015, he was named to Governor Chris Christie's Presidential Leadership team, and, last year he joined then candidate "Donald Trump for President" presidential run and then transition fundraising. Following that, Maoli served on the president's transition team.  Now that his enterprises have expanded to New York, Maoli also recently endorsed Richard "Bo" Dietl, who is running for Mayor of New York. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-jersey-business-leader-tom-maoli-supports-kim-guadagno-300462725.html


News Article | June 7, 2017
Site: www.prnewswire.com

"Atlantic Health System's annual Research Day Symposium is a testament to the innovative ways we are advancing and enhancing care delivery," said Brian Gragnolati, president and CEO, Atlantic Health System.  "As our industry moves toward personalized medicine, our research program drives progress for our patients and ensures our medical and clinical staff continue to have access to the latest medications, devices and technologies to provide exceptional patient care." Internationally recognized researcher C. Noel Bairey Merz, MD, director of the Barbra Streisand Women's Heart Center, the Linda Joy Pollin Women's Heart Health Program, and the Preventive Cardiac Center at the Cedars-Sinai Heart Institute, presented the keynote presentation: "Cardiovascular Disease: Do Sex, Gender, and Ethnicity Count?" As part of its vision of improving lives and empowering communities through health, hope, and healing, Atlantic Health System works with pharmaceutical companies and medical device manufacturers to conduct research across a wide range of therapeutic areas to help evaluate experimental drugs and drug combinations, medical devices and procedures. This ensures patients continually have access to the latest treatments, even before they are approved by the U.S. Food and Drug Administration. Further, many researchers choose to work at Atlantic Health System because it allows them to conduct high-quality research, while still continuing their clinical practice—a benefit not often seen in large health systems. For more information about research and clinical trials at Atlantic Health System, visit: http://research.atlantichealth.org About Atlantic Health System  Atlantic Health System, headquartered in Morristown, New Jersey, is a leading non-profit, clinically integrated health care system comprised of Atlantic Medical Group with more than 900 physicians and multispecialty care providers, medical centers, rehabilitation and urgent care. Atlantic Medical Group had more than 1.2 million patient visits in 2016. Locations include Morristown Medical Center in Morristown, NJ; Overlook Medical Center in Summit, NJ; Newton Medical Center in Newton, NJ; Chilton Medical Center in Pompton Plains, NJ; Hackettstown Medical Center in Hackettstown, NJ; and Goryeb Children's Hospital in Morristown, NJ, as well as Atlantic Rehabilitation Institute, and Atlantic Home Care and Hospice. It also includes its subsidiary, Atlantic Ambulance Corporation. Atlantic Health System comprises 1,747 licensed beds, nearly 16,000 employees and more than 3,700 physicians. Atlantic Health System has a medical school affiliation with the Sidney Kimmel Medical College at Thomas Jefferson University; is part of Atlantic Accountable Care Organization, one of the largest ACOs in the nation, and is a member of AllSpire Health Partners. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/atlantic-health-system-hosts-21st-annual-research-day-symposium-300470366.html


News Article | June 8, 2017
Site: www.prnewswire.co.uk

The TVT Innovation Forum, which takes place opening night, is the preeminent session featuring new technological developments in the field of transcatheter valve therapy. Martin B. Leon, MD and Gregg W. Stone, MD, two of TVT's course directors, will moderate the 1-hour session which begins at 7:00 pm on Wednesday, June 14 in the Sheraton Chicago Ballroom IV-VII. Philippe Généreux, MD will present "4C Medical Valve: A Novel Transcatheter MR Treatment Technology" at 7:48 pm and facilitate the subsequent roundtable discussion with audience Q&A. Dr. Généreux is Co-Director of the Structural Heart Program at the Gagnon Cardiovascular Institute of Morristown Medical Center (Morristown, NJ) and a practicing Interventional Cardiologist at Hôpital du Sacré-Coeur de Montréal (Montreal, Canada). "We are honored to be one of the five concepts recognized for its unique innovation," said Robert Thatcher, CEO of 4C Medical Technologies, Inc. "Our team has made significant progress over the past year to develop and evaluate the first-of-its-kind supra-annular implant design, and this presentation is the ideal forum to introduce our novel MR therapy to the clinical community." Mitral regurgitation (MR) is a common heart valve disease affecting nearly 10 percent of Americans aged ≥75 years.1 MR occurs when the mitral valve leaflets do not close properly and allow blood in the left ventricle to leak back into the left atrium. It is a progressive disease and if left untreated, MR can lead to atrial fibrillation, pulmonary hypertension, heart failure and death. 4C Medical Technologies, Inc. is a medical device company developing minimally invasive therapies for structural heart disease, focusing initially on mitral regurgitation (MR) therapy and subsequently on tricuspid regurgitation therapy. The company's unique supra-annular implant is the first MR therapy with atrial-only fixation, thereby eliminating known issues associated with transcatheter MR replacement technologies which rely on placement and fixation in the native mitral annulus and left ventricle.


Philippe Généreux, MD will present "4C Medical Valve: A Novel Transcatheter MR Treatment Technology" at 7:48 pm and facilitate the subsequent roundtable discussion with audience Q&A. Dr. Généreux is Co-Director of the Structural Heart Program at the Gagnon Cardiovascular Institute of Morristown Medical Center (Morristown, NJ) and a practicing Interventional Cardiologist at Hôpital du Sacré-Coeur de Montréal (Montreal, Canada). "We are honored to be one of the five concepts recognized for its unique innovation," said Robert Thatcher, CEO of 4C Medical Technologies, Inc. "Our team has made significant progress over the past year to develop and evaluate the first-of-its-kind supra-annular implant design, and this presentation is the ideal forum to introduce our novel MR therapy to the clinical community." Mitral regurgitation (MR) is a common heart valve disease affecting nearly 10 percent of Americans aged ≥75 years.1 MR occurs when the mitral valve leaflets do not close properly and allow blood in the left ventricle to leak back into the left atrium. It is a progressive disease and if left untreated, MR can lead to atrial fibrillation, pulmonary hypertension, heart failure and death. 4C Medical Technologies, Inc. is a medical device company developing minimally invasive therapies for structural heart disease, focusing initially on mitral regurgitation (MR) therapy and subsequently on tricuspid regurgitation therapy. The company's unique supra-annular implant is the first MR therapy with atrial-only fixation, thereby eliminating known issues associated with transcatheter MR replacement technologies which rely on placement and fixation in the native mitral annulus and left ventricle. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/4c-medicals-mitral-regurgitation-therapy-to-be-featured-in-2017-tvt-innovation-forum-300470752.html


News Article | June 15, 2017
Site: www.prnewswire.com

Dr. Généreux presented "4C Medical Valve: A Novel Transcatheter MR Treatment Technology" and facilitated subsequent roundtable discussions with audience Q&A. He is Co-Director of the Structural Heart Program at the Gagnon Cardiovascular Institute of Morristown Medical Center (Morristown, NJ) and a practicing Interventional Cardiologist at Hôpital du Sacré-Coeur de Montréal (Montreal, Canada). "The main challenges encountered by current TMVR devices are related to the complexity of the mitral valve anatomy and the multitude of MR mechanisms," said Dr. Généreux. "With its supra-annular position in the left atrium, the 4C Medical device preserves the native valve apparatus and avoids all issues related to the complexity and dynamism of the mitral annulus, making the device suitable for patients independent of their MR mechanism. This unique approach promotes healthy left ventricular remodeling and healing, and eliminates the complications that are associated with current TMVR devices, such as left ventricular outflow tract obstruction, device embolization and early device fatigue failure." "We are dedicated to innovating therapies for structural heart disease through clinical research in partnership with Key Opinion Leaders," said Robert Thatcher, CEO of 4C Medical Technologies, Inc. "More than half of symptomatic MR patients are not candidates for surgery, and we are driven to develop new solutions that clinicians can use to improve the quality of life for these patients." About Mitral Regurgitation Mitral regurgitation (MR) is a common heart valve disease affecting nearly 10 percent of Americans aged ≥75 years.1 MR occurs when the mitral valve leaflets do not close properly and allow blood in the left ventricle to leak back into the left atrium. It is a progressive disease and if left untreated, MR can lead to atrial fibrillation, pulmonary hypertension, heart failure and death. About 4C Medical Technologies, Inc. 4C Medical Technologies, Inc. is a medical device company developing minimally invasive therapies for structural heart disease, focusing initially on mitral regurgitation (MR) therapy and subsequently on tricuspid regurgitation therapy. The company's unique supra-annular implant is the first MR therapy with atrial-only fixation, thereby eliminating known issues associated with transcatheter MR replacement technologies which rely on placement and fixation in the native mitral annulus and left ventricle. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/4c-medicals-novel-mitral-regurgitation-therapy-highlighted-at-tvt-innovation-forum-300474255.html


« La valve mitrale de 4C Medical est une solution innovante et simple pour une affection très courante, et son mécanisme inédit permettra de traiter de nombreux patients pour lesquels les dispositifs TMVR actuels ne sont pas adaptés », explique le docteur Philippe Généreux, MD. « Les résultats précliniques sur 30 jours sont prometteurs et démontrent la faisabilité et l'innocuité du concept, sans compromis hémodynamique, sans thrombus et avec une MR de moyenne à nulle, comme l'a confirmé l'échocardiographie ». Le Dr Généreux a présenté « 4C Medical Valve: A Novel Transcatheter MR Treatment Technology » et animé ensuite une table ronde avec une séance de questions-réponses avec le public. Il est co-directeur du programme pour les maladies cardiaques structurelles au Gagnon Cardiovascular Institute of Morristown Medical Center (Morristown, New Jersey) et cardiologue interventionniste à l'Hôpital du Sacré-Cœur de Montréal (Montréal, Canada). « Les principales difficultés rencontrées avec les dispositifs TMVR actuels sont liées à la complexité de l'anatomie de la valve mitrale et à la multitude des mécanismes MR », selon le Dr Généreux. « Avec sa position supra-annulaire dans l'oreillette gauche, le dispositif 4C Medical préserve le mécanisme de valve natif et permet d'éviter tous les problèmes liés à la complexité et au dynamisme de l'anneau mitral, ce qui lui permet d'être utilisé chez les patients indépendamment de leur mécanisme MR. Cette approche inédite permet un remodelage et une guérison saine du ventricule gauche, et élimine les complications liées aux dispositifs TMVR actuels, comme l'obstruction du débit du ventricule gauche, l'embolisation du dispositif et une rupture précoce par fatigue ». A propos de 4C Medical Technologies, Inc. 4C Medical Technologies, Inc. est un fabricant de dispositifs médicaux qui met au point des thérapies minimalement invasives pour les maladies structurelles du cœur, et qui s'est d'abord intéressée au traitement de l'insuffisance mitrale (IM) pour s'intéresser ensuite au traitement de la régurgitation tricuspidienne. L'implant supra-annulaire inédit qu'elle propose est la première thérapie IM à faire appel à une fixation qui ne concerne que l'oreillette, et il permet d'éviter les problèmes connus d'autres technologies de remplacement IM par cathétérisme qui font appel à une pose et une fixation dans l'anneau mitral natif et le ventricule gauche.


Dr. Alistar comes to Atlantic Health System from the Wake Forest School of Medicine, where she led the GI oncology team, bringing cutting-edge treatments to patients. While there, she designed, secured funding for and conducted five investigator-initiated therapeutic clinical trials. At Wake Forest University she was the Principal Investigator of the Precision Oncology study that is poised to generate new hypotheses in the era of genomic driven clinical trials. "When evaluating the best programs across the country to continue my work, I chose Atlantic Health System due to its leaders' strong commitment to innovation, clinical research and patient-centered care and bringing the latest treatments to cancer patients," said Dr. Alistar.  "I look forward to expanding treatment options for patients with pancreatic cancer and other GI malignancies, and to working in a multidisciplinary fashion with my new colleagues at Atlantic Health System Cancer Care to improve treatment outcomes and develop new standards of care." Study of Pancreatic Cancer Drug Provides Hope for Difficult-to-Treat Patients In the new Lancet Oncology study, Dr. Alistar and colleagues conducted a Phase I clinical trial of CPI-613, in combination with a modified version of FOLFIRINOX, a current multidrug treatment regimen approved by the FDA for use in pancreatic cancer that has spread beyond the pancreas.  The trial was designed to determine the maximum tolerated dose of CPI-613 when used in combination with the modified FOLFIRINOX regimen in patients with Stage IV pancreatic cancer.  The study provided preliminary evidence of the drug combination's efficacy, as well as demonstrating its safety and tolerability. "This study gives me reason for hope," said Dr. Alistar.  "Patients with metastatic pancreatic cancer have a dismal prognosis, and the toxicity of current therapies limits their usefulness, underscoring the desperate need for safer, more effective treatments.  That is why I have dedicated my career to helping find effective therapies for pancreatic and other difficult-to-treat GI cancers." Dr. Alistar will serve as the Co-Principal Investigator with Dr. Philip Philip of Karmanos Cancer Center on a planned multi-center Phase II/III study of CPI-613 in combination with modified FOLFIRINOX for metastatic pancreatic cancer.  She has led four other clinical trials of CPI-613 for GI cancers, as well as studies of other novel oncology drugs, and research to determine disease processes and genetic factors in cancers of the gastrointestinal tract. CPI-613, developed by New Jersey-based Cornerstone Pharmaceuticals, is a new type of medication known as an altered energy metabolism directed (AEMD) drug.  It is the first anticancer drug of its kind.  It is designed to disrupt the altered energy production pathways in cancer cells by selectively targeting a process in cell multiplication and survival. Pancreatic cancer is the third leading cause of cancer-related death in the United States, with a five-year survival rate of just seven percent.  Fifty-three percent of patients are diagnosed with advanced disease. Dr. Alistar's primary focus at Wake Forest School of Medicine was on immuno-oncology and its application in treatment of gastrointestinal cancers of the pancreas, colon, rectum, bile duct and esophagus, as well as in treating melanoma. Her clinical research projects involved active collaborative efforts with other medical departments, such as radiation oncology and surgical oncology, as well as genetics. An assistant professor of internal medicine at Wake Forest before joining Atlantic Health, she was also a member of the Translational Cancer Genomics Committee, the GI Tumor Board, Internal Medicine Grand Rounds Committee, and the Hepatobiliary Oncology Committee. She is a member of the American Society of Clinical Oncology, the American Society of Hospice and Palliative Care Medicine, and the American Society of Hematology, among many other professional societies. She also serves as a member and advisor to several other health care organizations.  She is certified by the American Board of Internal Medicine, in both internal medicine and medical oncology. Dr. Alistar received her medical degree from University of Medicine and Pharmacy, Cluj Napoca, Romania, and conducted her internship and residency at Englewood Hospital and Medical Center, where she was chief resident. After her residency, she was a fellow in hematology and medical oncology at Mount Sinai School of Medicine, Tisch Cancer Institute. She currently serves as an ad hoc reviewer for JAMA and was recently the recipient of the Danny Danielson Translational Innovation Award for her dedication to clinical research. Dr. Alistar is a physician with Atlantic Hematology Oncology at the Carol G. Simon Cancer Center -Morristown Medical Center campus.  Dr. Alistar can be reached at 973-971-7960. Dr. Alistar is affiliated with Atlantic Medical Group, and is a participating provider in the Atlantic Accountable Care Organization. About Atlantic Health System -  Atlantic Health System, headquartered in Morristown, New Jersey, is a leading non-profit health care delivery system in New Jersey. Our network includes Morristown Medical Center in Morristown, NJ; Overlook Medical Center in Summit, NJ; Newton Medical Center in Newton, NJ; Chilton Medical Center in Pompton Plains, NJ; Hackettstown Medical Center in Hackettstown, NJ; and Goryeb Children's Hospital in Morristown, NJ, as well as Atlantic Rehabilitation, and Atlantic Home Care and Hospice. It also includes its subsidiary, Atlantic Ambulance Corporation. Atlantic Health System comprises 1,747 licensed beds, more than 14,000 employees and more than 4,000 physicians. Atlantic Health System has a medical school affiliation with the Sidney Kimmel Medical College at Thomas Jefferson University; is part of Atlantic Accountable Care Organization, one of the largest ACOs in the nation, and is a member of AllSpire Health Partners. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dr-angela-alistar-national-leader-in-gastrointestinal-cancer-research-joins-atlantic-health-system-cancer-care-as-medical-director-gi-medical-oncology-300467648.html


Slomovitz B.M.,Morristown Medical Center | Slomovitz B.M.,University of Houston | Coleman R.L.,University of Houston
Clinical Cancer Research | Year: 2012

Endometrial cancer is the most common gynecologic malignancy in the United States. Overactivation of the PI3K/AKT/mTOR pathway, a signaling pathway that plays an important role in cellular growth and survival, has recently been implicated in endometrial cancer pathogenesis, and as such, inhibition of the PI3K/AKT/mTOR pathway is of therapeutic interest. Preclinical and clinical studies are proving useful in elucidating the antitumor effects of different PI3K/AKT/mTOR pathway inhibitors, and in defining which patient populations these inhibitors might be most effective in. For example, an increasing amount of preclinical data suggest that loss of PTEN or genetic alteration of PIK3CA may be indicators of sensitivity to PI3K/AKT/mTOR pathway inhibition, while activating KRAS mutations may predict resistance. In the latter case, combined inhibition of the RAS/RAF/MEK and PI3K/AKT/mTOR pathways has been suggested as a therapeutic strategy. In addition, the PI3K/AKT/mTOR pathway has been implicated in conferring resistance to conventional therapies, and so PI3K/AKT/mTOR pathway inhibitors in combination with hormonal and/or cytotoxic agents are being evaluated. In conclusion, preclinical models are providing insights into the antitumor activity of PI3K/AKT/mTOR pathway inhibition, and are helping define patient populations most likely to benefit from these therapies. Clinical validation of these findings is ongoing. ©2012 AACR.


Fiel S.B.,Morristown Medical Center
Expert Review of Respiratory Medicine | Year: 2014

Inhaled antibiotic therapy, targeting Pseudomonas aeruginosa, is a fundamental component of cystic fibrosis (CF) management. Tobramycin inhalation solution (TIS) was approved in the United States (US) in 1998. Subsequent research efforts focused on developing products with a reduced treatment time burden. Aztreonam for inhalation solution (AZLI), administered via a more efficient nebulizer than TIS, was approved in the US in 2010. Dry powder for inhalation (DPI) formulations provide alternatives to nebulized therapy: tobramycin powder for inhalation (also known as TIP™) was approved in the US in 2013, and colistimethate sodium DPI received European approval in 2012. Other aerosolized antibiotics and regimens combining inhaled antibiotics are in development. Inhaled antibiotic rotation (e.g., TIS alternating with AZLI) is an important concept being actively tested in CF. © Informa Uk, Ltd.

Loading Morristown Medical Center collaborators
Loading Morristown Medical Center collaborators